Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
about
Recent advances in understanding myelofibrosis and essential thrombocythemiaInflammation as a Keystone of Bone Marrow Stroma Alterations in Primary MyelofibrosisMomelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.Clinical significance of microcytosis in patients with primary myelofibrosis.Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.Elevated Hepcidin Is Part of a Complex Relation That Links Mortality with Iron Homeostasis and Anemia in Men and Women with HIV Infection.Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial.High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Investigational Janus kinase inhibitors in development for myelofibrosis.Transforming growth factor 15 increased in severe aplastic anemia patients.Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.Treatment of Myelofibrosis: Old and New Strategies.Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosisDiagnosis of iron-deficient states.
P2860
Q26748543-A1CA7CCD-BBF9-466D-A9FC-EC76D97C80E7Q26774212-F5D96D7F-951E-4CA9-A868-329CEBB247BEQ30244032-4F44F54E-FB58-4904-8F17-80C5837BAA76Q33431469-657BE705-8AAC-4A60-BB08-92358AEBA5A4Q34276194-AE3EBEE3-9DE7-4AB2-88FC-CB79B3E455B9Q35414429-01346578-892A-48C9-BB87-10FDD1803349Q35640004-6AB2D925-412E-4056-B7A4-E80B3F6F1B37Q35976594-46491F43-BB2A-43C7-9F7C-ABA0D1454210Q37144881-04250835-C62C-4E6D-A565-A903BA0E3AF7Q37609241-3BD936FD-8A7A-4D95-8901-92B732038B2AQ38174781-51FA3D3D-BC84-4C94-B65C-66E1E0855538Q38239580-6BF3E23E-F7A0-4998-B9CD-BD61CDE7A331Q38567540-75B22017-BF80-48B2-8C13-67FEB524B324Q38691019-DF898F97-801B-437B-8BE1-5AB06ECD8DE4Q38849609-C8DB5995-3E25-476E-B56C-64D96F56B02EQ38966659-D922A94D-0441-4C7C-8CA8-6C0B7B77F977Q39349869-6C7659A5-EA39-4AC1-ACA7-D9948E06D1DDQ41980585-9441EAF8-D15B-4EFD-826F-8FAA5D2328ABQ50438163-FAFDD2E7-6CA8-4244-9CAD-CCF8054A2C59
P2860
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Associations and prognostic in ...... ines in primary myelofibrosis.
@en
Associations and prognostic in ...... ines in primary myelofibrosis.
@nl
type
label
Associations and prognostic in ...... ines in primary myelofibrosis.
@en
Associations and prognostic in ...... ines in primary myelofibrosis.
@nl
prefLabel
Associations and prognostic in ...... ines in primary myelofibrosis.
@en
Associations and prognostic in ...... ines in primary myelofibrosis.
@nl
P2093
P2860
P356
P1476
Associations and prognostic in ...... ines in primary myelofibrosis.
@en
P2093
Animesh Pardanani
Christy Finke
Ramy A Abdelrahman
Terra L Lasho
P2860
P304
P356
10.1002/AJH.23406
P577
2013-02-28T00:00:00Z